Aastrom Announces Collaboration with CPC for Phase 3 Revive StudyGates Center May 25, 2011
Aastrom Announces Collaboration with CPC Clinical Research for the Phase 3 REVIVE Study in Critical Limb Ischemia
ANN ARBOR, Mich., [May 25, 2011] - Aastrom Biosciences, Inc. (Nasdaq: ASTM), a leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced a collaborative agreement with CPC Clinical Research (CPC), a non-profit, Academic Research Organization led by William Hiatt, M.D. CPC will provide services related to the execution of Aastrom’s Phase 3 REVIVE clinical studies for ixmyelocel-T, the company’s expanded multicellular therapy.
View full press release >>